Compare RVSB & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSB | TTRX |
|---|---|---|
| Founded | 1923 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.2M | 107.2M |
| IPO Year | 1997 | N/A |
| Metric | RVSB | TTRX |
|---|---|---|
| Price | $5.75 | $5.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | ★ $8.00 |
| AVG Volume (30 Days) | 41.2K | ★ 61.6K |
| Earning Date | 04-28-2026 | 05-31-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.74 | $2.57 |
| 52 Week High | $6.22 | $6.75 |
| Indicator | RVSB | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.53 | 58.41 |
| Support Level | $4.96 | $4.09 |
| Resistance Level | $6.22 | $6.75 |
| Average True Range (ATR) | 0.23 | 0.64 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 43.24 | 54.23 |
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.